Olmesartan belongs to the angiotensin II receptor antagonist, and its main effects include lowering blood pressure, improving ventricular remodeling, and reducing urinary protein. Olmesartan is a commonly used first-line therapeutic class of antihypertensive drugs in the clinic, and similar drugs include chlorosartan, valsartan, and irbesartan. The drug is able to inhibit the release of renin-angiotensin-aldosterone by blocking the angiotensin receptor, thus dilating blood vessels to play a role in lowering blood pressure. Secondly, the drug is also able to prevent the occurrence of ventricular remodeling by inhibiting the renin-angiotensin-aldosterone system, thereby reducing the neuroendocrine effects on the myocardium. In addition, olmesartan dilates the glomerular outflow arterioles more than the inlet arterioles, thus reducing the glomerular high pressure and hyperperfusion, thus reducing the loss of proteins and lowering the effect of urinary proteins. Olmesartan is suitable for people with hypertension accompanied by heart failure, diabetic nephropathy, ventricular hypertrophy, coronary heart disease and other diseases, as well as taking angiotensin-converting enzyme inhibitors such as enalapril and other coughing symptoms of the population can also be used.